Infrequent Zoledronate - Small Individual Gain, Larger Population Gain [0.03%]
唑来膦酸不规律用药：个人收益微小，人群获益更大
Roland Chapurlat
Roland Chapurlat
Simone Sanna-Cherchi
Simone Sanna-Cherchi
Stefan Blankenberg
Stefan Blankenberg
Case 2-2025: A 21-Year-Old Man with Loss of Consciousness and a Fall [0.03%]
病例分析2-2025：一名21岁男子因意识丧失和跌倒就诊
Eric F Shappell,Brooks P Applewhite,Sharl S Azar et al.
Eric F Shappell et al.
Livedo Racemosa [0.03%]
livedo racemosa
Wei-Yao Wang,Cheng-Che Eric Lan
Wei-Yao Wang
Atilla Emin,Nagarjun Konda,Matthew Venus
Atilla Emin
Paul S Haber
Paul S Haber
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer [0.03%]
残留HER2阳性乳腺癌患者接受曲妥珠单抗衍生物治疗的生存情况
Charles E Geyer Jr,Michael Untch,Chiun-Sheng Huang et al.
Charles E Geyer Jr et al.
Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death. The primar...
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age [0.03%]
低剂量唑来膦酸钠防治50至60岁女性骨折试验
Mark J Bolland,Zaynah Nisa,Anna Mellar et al.
Mark J Bolland et al.
Background: Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent zoledronate administration wo...
Randomized Controlled Trial
The New England journal of medicine. 2025 Jan 16;392(3):239-248. DOI:10.1056/NEJMoa2407031 2025
The Future of Gender-Affirming Care - A Law and Policy Perspective on the Cass Review [0.03%]
关于卡斯审查的法律和政策视角——性别确认护理的未来
Daniel G Aaron,Craig Konnoth
Daniel G Aaron